Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 1999 May;52(5):376-80.
doi: 10.1136/jcp.52.5.376.

Fluconazole versus itraconazole for the prevention of fungal infections in haemato-oncology

Affiliations
Clinical Trial

Fluconazole versus itraconazole for the prevention of fungal infections in haemato-oncology

P C Huijgens et al. J Clin Pathol. 1999 May.

Abstract

Aims: To compare the efficacy of and tolerance to oral fluconazole and intraconazole in preventing fungal infection in neutropenic patients with haematological malignancies.

Patients: 213 consecutive, afebrile adult patients treated with or without autologous stem cell transplantation for haematological malignancies.

Methods: A randomised, double blind, single centre study. Patients were randomly assigned to receive fluconazole 50 mg or itraconazole 100 mg, both twice daily in identical capsules. An intention to treat analysis was performed on 202 patients, 101 in each group.

Results: Microbiologically documented systemic fungal infections occurred in four patients in each group. Clinical fungal infection was thought to be present in seven recipients of fluconazole and four of itraconazole. In all 202 patients, 29 proceeded to intravenous amphotericin (amphotericin B), 16 in the fluconazole group and 13 in the itraconazole group. Superficial fungal infection was seen only in three non-compliant patients in the fluconazole group. All these infections were oral. No major differences were noted in the isolates of fungi in mouth washes and fecal samples. Overall mortality was 8.9% (18 deaths; seven in the fluconazole group, 11 in the itraconazole group). Mortality from microbiologically and clinically documented fungal infection was 4.5% (nine deaths; three in the fluconazole group, six in the itraconazole group). Median time to suspected or proven fungal infection was 16 days in both groups. None of these comparisons reached statistical significance (p < 0.05). No major clinical toxicity was noted and compliance was excellent.

Conclusions: In neutropenic patients treated for haematological malignancies with or without autologous stem cell transplantation, fluconazole and itraconazole in low doses result in a similar low frequency of fungal disease. Fluconazole may be the preferable drug because of the smaller number of capsules and lack of need for timing relative to meals.

PubMed Disclaimer

Similar articles

Cited by

References

    1. Bone Marrow Transplant. 1994 Dec;14(6):919-24 - PubMed
    1. Chemotherapy. 1995 Jan-Feb;41(1):39-44 - PubMed
    1. Ann Intern Med. 1996 Aug 1;125(3):183-90 - PubMed
    1. J Antimicrob Chemother. 1996 May;37(5):975-86 - PubMed
    1. Clin Infect Dis. 1997 Feb;24(2):235-47 - PubMed

Publication types